1. Home
  2. GAUZ vs CHRS Comparison

GAUZ vs CHRS Comparison

Compare GAUZ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAUZ
  • CHRS
  • Stock Information
  • Founded
  • GAUZ 2009
  • CHRS 2010
  • Country
  • GAUZ Israel
  • CHRS United States
  • Employees
  • GAUZ N/A
  • CHRS N/A
  • Industry
  • GAUZ Industrial Machinery/Components
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GAUZ Miscellaneous
  • CHRS Health Care
  • Exchange
  • GAUZ Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • GAUZ 102.0M
  • CHRS 159.2M
  • IPO Year
  • GAUZ 2024
  • CHRS 2014
  • Fundamental
  • Price
  • GAUZ $5.87
  • CHRS $1.35
  • Analyst Decision
  • GAUZ Strong Buy
  • CHRS Strong Buy
  • Analyst Count
  • GAUZ 3
  • CHRS 4
  • Target Price
  • GAUZ $13.67
  • CHRS $4.51
  • AVG Volume (30 Days)
  • GAUZ 55.6K
  • CHRS 1.2M
  • Earning Date
  • GAUZ 11-11-2025
  • CHRS 11-05-2025
  • Dividend Yield
  • GAUZ N/A
  • CHRS N/A
  • EPS Growth
  • GAUZ N/A
  • CHRS N/A
  • EPS
  • GAUZ N/A
  • CHRS 1.55
  • Revenue
  • GAUZ $96,810,000.00
  • CHRS $272,209,000.00
  • Revenue This Year
  • GAUZ $23.16
  • CHRS N/A
  • Revenue Next Year
  • GAUZ $40.82
  • CHRS $109.48
  • P/E Ratio
  • GAUZ N/A
  • CHRS $0.87
  • Revenue Growth
  • GAUZ 7.87
  • CHRS 52.33
  • 52 Week Low
  • GAUZ $4.54
  • CHRS $0.66
  • 52 Week High
  • GAUZ $13.00
  • CHRS $2.43
  • Technical
  • Relative Strength Index (RSI)
  • GAUZ 53.75
  • CHRS 64.99
  • Support Level
  • GAUZ $5.37
  • CHRS $1.23
  • Resistance Level
  • GAUZ $6.00
  • CHRS $1.40
  • Average True Range (ATR)
  • GAUZ 0.35
  • CHRS 0.08
  • MACD
  • GAUZ 0.12
  • CHRS -0.00
  • Stochastic Oscillator
  • GAUZ 90.75
  • CHRS 72.13

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: